https://www.selleckchem.com/products/kya1797k.html
9 per 100 patient-year, major bleeding in 1.7 and all-cause deaths in 6.0 per 100 patient-year. No fatal bleeding or fatal VTE recurrence were observed. During 232.1 patient-years of follow-up after DOAC withdrawal, recurrent VTE occurred in 3.0 per 100 patient-year. The 2019 ESC categories for risk of VTE recurrences were able to discriminate patient groups at different risk of events in the on and off-treatment periods. Our data support the feasibility as well as the effectiveness and safety of DOACs for the treatment of acute UEDVT.
Like
Comment
Share
